The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing you cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Brentuximab vedotin approved in Japan for frontline treatment of HL

Sep 24, 2018

Brentuximab vedotin has received approval by the Japanese Ministry of Health, Labour and Welfare, for the frontline treatment of CD30+ Hodgkin lymphoma (HL) in combination with doxorubicin, vinblastine and dacarbazine (AVD). 

This approval follows results from the ECHELON-1 trial. Results from the ECHELON-1 phase III study were presented during a plenary scientific session at the 59th Annual Meeting & Exposition of the American Society of Hematology (ASH) in Atlanta, GA, on December 10th, 2017. Professor Anas Younes commented on the outcomes of the study in an interview with the Lymphoma Hub.